Nimbus Therapeutics, Inc.

Included for 2025 are investors, CEOs of small and mid-sized companies, rising employees in larger businesses, and individuals spearheading unique health initiatives worldwide. The 30 individuals list

The stats are known by now: 90% of drug candidates fail during the development process. While artificial intelligence (AI) is touted for its potential to reduce the overall failure rate, a more modest

It has been less than three years since Atlas Venture closed its thirteenth venture capital fund and one thing is unchanged with its fourteenth – the size of the fund. Atlas announced on 5 December th

While early 2023 saw COVID-19 finally fading away, other global crises continued throughout the year (Russia-Ukraine invasion) or were newly created (Israel-Hamas conflict). In short, the socioeconomi